Spero Therapeutics Inc. (SPRO)
Spero Therapeutics Statistics
Share Statistics
Spero Therapeutics has 55.9M shares outstanding. The number of shares has increased by 0.98% in one year.
| Shares Outstanding | 55.9M |
| Shares Change (YoY) | 0.98% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 28.97% |
| Shares Floating | 37.55M |
| Failed to Deliver (FTD) Shares | 57 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 498.07K, so 0.91% of the outstanding shares have been sold short.
| Short Interest | 498.07K |
| Short % of Shares Out | 0.91% |
| Short % of Float | 1.11% |
| Short Ratio (days to cover) | 3.45 |
Valuation Ratios
The PE ratio is -0.81 and the forward PE ratio is -1.48. Spero Therapeutics's PEG ratio is 0.
| PE Ratio | -0.81 |
| Forward PE | -1.48 |
| PS Ratio | 1.16 |
| Forward PS | 0.4 |
| PB Ratio | 1.21 |
| P/FCF Ratio | -2.37 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Spero Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.19, with a Debt / Equity ratio of 0.09.
| Current Ratio | 2.19 |
| Quick Ratio | 2.19 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | -0.06 |
| Debt / FCF | -0.18 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.5M |
| Profits Per Employee | $-2.14M |
| Employee Count | 32 |
| Asset Turnover | 0.43 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -48.98% in the last 52 weeks. The beta is 0.64, so Spero Therapeutics's price volatility has been higher than the market average.
| Beta | 0.64 |
| 52-Week Price Change | -48.98% |
| 50-Day Moving Average | 0.76 |
| 200-Day Moving Average | 1.1 |
| Relative Strength Index (RSI) | 54.7 |
| Average Volume (20 Days) | 177.42K |
Income Statement
In the last 12 months, Spero Therapeutics had revenue of 47.98M and earned -68.57M in profits. Earnings per share was -1.27.
| Revenue | 47.98M |
| Gross Profit | 47.98M |
| Operating Income | -73.36M |
| Net Income | -68.57M |
| EBITDA | -72.48M |
| EBIT | -72.48M |
| Earnings Per Share (EPS) | -1.27 |
Balance Sheet
The company has 52.89M in cash and 4.3M in debt, giving a net cash position of 48.59M.
| Cash & Cash Equivalents | 52.89M |
| Total Debt | 4.3M |
| Net Cash | 48.59M |
| Retained Earnings | -459.64M |
| Total Assets | 110.54M |
| Working Capital | 58.2M |
Cash Flow
In the last 12 months, operating cash flow was -23.44M and capital expenditures 0, giving a free cash flow of -23.44M.
| Operating Cash Flow | -23.44M |
| Capital Expenditures | 0 |
| Free Cash Flow | -23.44M |
| FCF Per Share | -0.43 |
Margins
Gross margin is 100%, with operating and profit margins of -152.91% and -142.91%.
| Gross Margin | 100% |
| Operating Margin | -152.91% |
| Pretax Margin | -142.91% |
| Profit Margin | -142.91% |
| EBITDA Margin | -151.08% |
| EBIT Margin | -152.91% |
| FCF Margin | -48.87% |
Dividends & Yields
SPRO pays an annual dividend of $0.07, which amounts to a dividend yield of 0.52%.
| Dividend Per Share | $0.07 |
| Dividend Yield | 0.52% |
| Dividend Growth (YoY) | 0% |
| Payout Ratio | -5.91% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for SPRO is $5, which is 566.7% higher than the current price. The consensus rating is "Hold".
| Price Target | $5 |
| Price Target Difference | 566.7% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -6.69 |
| Piotroski F-Score | 2 |